Mersana Therapeutics Inc (MRSN) - Total Liabilities
Based on the latest financial reports, Mersana Therapeutics Inc (MRSN) has total liabilities worth $122.22 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MRSN cash generation efficiency to assess how effectively this company generates cash.
Mersana Therapeutics Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Mersana Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Mersana Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Mersana Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Mersana Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Serviceware SE
F:SJJ
|
Germany | €122.10 Million |
|
Trada Maritime Tbk
JK:TRAM
|
Indonesia | Rp1.31 Trillion |
|
GEVORKYAN as
PR:GEV
|
Czech Republic | Kč128.65 Million |
|
Komplett AS
OL:KOMPL
|
Norway | Nkr4.61 Billion |
|
Wam Strategic Value Ltd
AU:WAR
|
Australia | AU$6.49 Million |
|
Fwusow Industry Co Ltd
TW:1219
|
Taiwan | NT$5.03 Billion |
|
Lima Dua Lima Tiga PT
JK:LUCY
|
Indonesia | Rp57.69 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Mersana Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MRSN stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.95 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mersana Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mersana Therapeutics Inc (2015–2024)
The table below shows the annual total liabilities of Mersana Therapeutics Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $154.17 Million | -18.49% |
| 2023-12-31 | $189.16 Million | -21.93% |
| 2022-12-31 | $242.28 Million | +187.17% |
| 2021-12-31 | $84.37 Million | +86.20% |
| 2020-12-31 | $45.31 Million | +55.06% |
| 2019-12-31 | $29.22 Million | -58.08% |
| 2018-12-31 | $69.71 Million | +14.80% |
| 2017-12-31 | $60.72 Million | -62.22% |
| 2016-12-31 | $160.71 Million | +181.44% |
| 2015-12-31 | $57.10 Million | -- |
About Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial.… Read more